Dr. Reddy's Laboratories (RDY) Competitors $14.00 +0.17 (+1.23%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$14.01 +0.01 (+0.10%) As of 05/2/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. ARGX, BNTX, ONC, SMMT, TEVA, ITCI, GMAB, MRNA, ASND, and VTRSShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. argenx BioNTech Beigene Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Moderna Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories (NYSE:RDY) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Does the media favor RDY or ARGX? In the previous week, argenx had 8 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 16 mentions for argenx and 8 mentions for Dr. Reddy's Laboratories. argenx's average media sentiment score of 1.20 beat Dr. Reddy's Laboratories' score of 1.12 indicating that argenx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenx 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, RDY or ARGX? Dr. Reddy's Laboratories has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Do analysts recommend RDY or ARGX? Dr. Reddy's Laboratories currently has a consensus target price of $17.00, suggesting a potential upside of 21.43%. argenx has a consensus target price of $699.28, suggesting a potential upside of 7.64%. Given Dr. Reddy's Laboratories' higher probable upside, equities research analysts plainly believe Dr. Reddy's Laboratories is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50argenx 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.91 Does the MarketBeat Community favor RDY or ARGX? argenx received 336 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.38% of users gave argenx an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% argenxOutperform Votes65767.38% Underperform Votes31832.62% Which has preferable valuation and earnings, RDY or ARGX? Dr. Reddy's Laboratories has higher revenue and earnings than argenx. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6322.22argenx$2.19B18.11-$295.05M$12.5951.60 Is RDY or ARGX more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to argenx's net margin of -2.11%. Dr. Reddy's Laboratories' return on equity of 17.87% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% argenx -2.11%-1.45%-1.29% Do institutionals & insiders have more ownership in RDY or ARGX? 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Summaryargenx beats Dr. Reddy's Laboratories on 12 of the 19 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$11.69B$6.85B$5.55B$19.20BDividend Yield0.58%2.96%5.09%4.00%P/E Ratio22.297.4722.7133.50Price / Sales0.04258.18405.5829.18Price / Cash13.2565.8538.1817.52Price / Book3.116.566.794.55Net Income$668M$143.41M$3.22B$1.02B7 Day Performance1.38%3.36%3.33%2.29%1 Month Performance5.78%10.30%6.89%2.93%1 Year Performance-6.93%-3.67%16.20%4.67% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories1.7388 of 5 stars$14.00+1.2%$17.00+21.4%-6.4%$11.69B$311.31B22.2924,800Upcoming EarningsPositive NewsARGXargenx2.5752 of 5 stars$620.97+1.0%$699.28+12.6%+65.1%$37.92B$2.19B-705.65650Upcoming EarningsPositive NewsBNTXBioNTech2.6238 of 5 stars$104.00+1.9%$143.44+37.9%+13.8%$24.96B$2.75B-49.523,080Upcoming EarningsPositive NewsHigh Trading VolumeONCBeigene1.8164 of 5 stars$249.46+1.9%$318.88+27.8%N/A$24.66B$3.81B-30.279,000Analyst RevisionNews CoverageSMMTSummit Therapeutics2.9037 of 5 stars$24.11+2.7%$37.50+55.5%+587.2%$17.79B$700,000.00-86.10110Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeTEVATeva Pharmaceutical Industries3.1375 of 5 stars$15.03+1.1%$23.43+55.9%+15.2%$17.04B$16.54B-10.3736,800Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsGap UpITCIIntra-Cellular Therapies0.9174 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4503 of 5 stars$20.63+0.2%$39.17+89.9%-22.5%$13.66B$21.53B11.861,660Upcoming EarningsMRNAModerna4.3397 of 5 stars$27.46+0.9%$58.70+113.8%-78.0%$10.62B$3.20B-2.963,900Earnings ReportAnalyst ForecastNews CoverageGap UpASNDAscendis Pharma A/S2.3478 of 5 stars$164.88+0.4%$204.67+24.1%+21.9%$10.05B$363.64M-23.22640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsVTRSViatris1.573 of 5 stars$8.25+1.5%$10.50+27.3%-25.4%$9.85B$14.74B-11.1537,000Upcoming Earnings Related Companies and Tools Related Companies argenx Alternatives BioNTech Alternatives Beigene Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Moderna Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RDY Stock Free RDY Stock Alerts